OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sharma Discusses Immunotherapy in Prostate Cancer

October 5th 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immunotherapy in prostate cancer.

Dr. Oxnard Discusses RET Fusions in NSCLC

October 4th 2018

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, Dana-Farber Cancer Institute, discusses RET fusions in non–small cell lung cancer.

Dr. Cohen on Immunotherapeutic Advances in Head and Neck Cancer

October 4th 2018

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapeutic advances in head and neck cancer.

Dr. Chien on Treatment Duration in HER2+ Breast Cancer

October 4th 2018

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment duration in HER2-positive breast cancer.

Dr. Naidoo on the Mechanisms Behind Immune-Related Adverse Events in Lung Cancer

October 4th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses the mechanisms behind immune-related adverse events (irAEs) in lung cancer.

Dr. Yacoub on Pegylated Interferon Treatment for PV

October 4th 2018

Abdulraheem Yacoub, MD, associate professor of medicine, University of Kansas Medical Center, discusses the potential of pegylated interferon treatment in patients with polycythemia vera.

Dr. Upadhyaya on the Design of the SJYC07 Trial in Pediatric Patients With Ependymoma

October 4th 2018

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses the design of the 10-year-long SJYC07 trial.

Dr. Tewari on the Trial Design With Cemiplimab in Cervical Cancer

October 4th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the trial design with cemiplimab (Libtayo) in recurrent or metastatic cervical cancer.

Dr. Green on Early Relapse in Multiple Myeloma

October 4th 2018

Michael Green, MD, Northern California Oncologist, discusses early relapse in multiple myeloma.

Dr. Rule on Watching and Waiting Approach For MCL Subset

October 3rd 2018

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the “watching and waiting” approach for a subset of patients with mantle cell lymphoma.

Dr. Allison Discusses the Future of Immunotherapy in Cancer Care

October 2nd 2018

James P. Allison, PhD, chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, and a recipient of the 2018 Nobel Prize in Physiology or Medicine, discusses the future of immunotherapy in the treatment of patients with cancer.

Dr. Formenti on Recent Progress With HER2-Targeted Therapy

October 2nd 2018

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the recent progress with HER2-targeted therapy in the treatment of breast cancer.

Dr. Ellis on Adjuvant CDK4/6 Inhibition in HR-Positive Breast Cancer

October 2nd 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses adjuvant CDK4/6 inhibition in hormone receptor (HR)-positive breast cancer.

Dr. Stadler on Approved and Investigational Therapies in RCC

October 2nd 2018

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses approved and investigational therapies in renal cell carcinoma (RCC).

Dr. Steinberg on the Management of Prostate Cancer

October 2nd 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the management of patients with prostate cancer.

Dr. Liu on Sequencing Therapy in ALK-Positive NSCLC

October 2nd 2018

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses sequencing strategies for patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Kaplan on the Combination of Ibrutinib and Venetoclax in MCL

October 2nd 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Dr. McGregor on Immunotherapy in Rare Genitourinary Cancers

October 2nd 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses immunotherapy in rare genitourinary (GU) cancers.

Dr. Pinato on PD-L1 Testing in HCC

October 2nd 2018

David J. Pinato, MD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses the role of PD-L1 testing in hepatocellular carcinoma.

Dr. Raje on Quadruplet Regimens in Myeloma

October 1st 2018

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the potential of quadruplet regimens in the multiple myeloma treatment paradigm.